Greenwich Therapeutics

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy designed to prevent breast cancer recurrences in patients who have previously undergone surgery. The company's lead candidate, GP2, is a 9-amino acid transmembrane peptide derived from the HER2/neu protein. GP2 is currently being evaluated in the Phase 3 FLAMINGO-01 clinical trial, which targets patients with HER2/neu 1+/2+ breast cancer. The treatment is administered in combination with GM-CSF to stimulate a potent T-cell response and has shown promising results in reducing recurrence rates in clinical studies. Headquartered in Texas, the company is dedicated to addressing the unmet need for adjuvant therapies in the oncology space. Greenwich LifeSciences is publicly traded on the NASDAQ exchange under the symbol GLSI.